AGIO Insider David T. Scadden Files Form 144 for 200 Shares
Rhea-AI Filing Summary
Form 144 filed for Agios Pharmaceuticals (AGIO) reporting proposed sale of common shares by an insider. The notice identifies David T. Scadden as the person for whose account the securities will be sold. The filing shows 200 shares intended for sale through Morgan Stanley Smith Barney LLC on 09/30/2025 with an aggregate market value of $8,000. The shares were acquired by a stock option exercise on 09/30/2025 and paid for in cash. The filing also discloses two prior sales by the reporting person within the past three months: 200 shares on 08/27/2025 for $8,000 and 1,400 shares on 07/10/2025 for $56,000. The notice includes the required representation that the seller does not possess undisclosed material adverse information.
Positive
- Disclosure compliance: The filer has submitted a Form 144 with broker details and transaction dates, meeting Rule 144 reporting requirements.
- Transaction transparency: The filing specifies acquisition method (stock option exercise), payment in cash, and broker information.
Negative
- Insider selling activity: The reporting person sold 1,600 shares in the past three months for gross proceeds of $64,000, which may attract investor attention.
- No 10b5-1 plan date provided: The form does not indicate a trading-plan adoption date, so sales are not documented as pre-planned in this filing.
Insights
TL;DR: An insider reported small, routine sales totaling 1,600 shares over three months; the new planned sale is 200 shares valued at $8,000.
The filing documents routine Rule 144 reporting for insider sales rather than corporate events. The prospective sale of 200 shares
TL;DR: Filing meets Rule 144 disclosure requirements; no plan adoption date or 10b5-1 plan is indicated.
The notice includes the statutory certification regarding absence of undisclosed material adverse information and lists broker details and transaction mechanics